-
Something wrong with this record ?
Pharmacotherapy of arterial hypertension in patients with psoriasis
J. Dodulík, L. Dodulíková, J. Plášek, Z. Ramík, J. Vrtal, J. Václavík
Language English Country Netherlands
Document type Journal Article, Review
- MeSH
- Mineralocorticoid Receptor Antagonists therapeutic use MeSH
- Antihypertensive Agents * therapeutic use MeSH
- Adrenergic beta-Antagonists therapeutic use adverse effects MeSH
- Calcium Channel Blockers therapeutic use MeSH
- Hypertension * drug therapy complications MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Humans MeSH
- Psoriasis * drug therapy complications MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients with psoriasis, arterial hypertension treatment requires careful selection of antihypertensive drugs, as some drugs may worsen the skin manifestations of psoriasis. In this review, we summarize the available evidence regarding the risks and benefits of each group of antihypertensive drugs. We also suggest a scheme for optimizing antihypertensive treatment in patients with psoriasis, with emphasis on achieving effective control of blood pressure and cardiovascular disease, while minimizing the worsening of cutaneous manifestations. Angiotensin receptor blockers appear to be the most appropriate treatment for hypertensive patients with psoriasis, with the potential addition of calcium channel blockers if blood pressure is not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid receptor antagonists. Diuretics and beta blockers are associated with greater risk of worsening of psoriatic lesions.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009343
- 003
- CZ-PrNML
- 005
- 20250429134704.0
- 007
- ta
- 008
- 250415s2025 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HJH.0000000000003982 $2 doi
- 035 __
- $a (PubMed)39976197
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Dodulík, Jozef $u Department of Internal Medicine and Cardiology, University Hospital Ostrava $u Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 245 10
- $a Pharmacotherapy of arterial hypertension in patients with psoriasis / $c J. Dodulík, L. Dodulíková, J. Plášek, Z. Ramík, J. Vrtal, J. Václavík
- 520 9_
- $a Psoriasis is a chronic systemic autoimmune disease associated with an elevated risk of developing cardiovascular disease. In patients with psoriasis, arterial hypertension treatment requires careful selection of antihypertensive drugs, as some drugs may worsen the skin manifestations of psoriasis. In this review, we summarize the available evidence regarding the risks and benefits of each group of antihypertensive drugs. We also suggest a scheme for optimizing antihypertensive treatment in patients with psoriasis, with emphasis on achieving effective control of blood pressure and cardiovascular disease, while minimizing the worsening of cutaneous manifestations. Angiotensin receptor blockers appear to be the most appropriate treatment for hypertensive patients with psoriasis, with the potential addition of calcium channel blockers if blood pressure is not adequately controlled. Alternatives are angiotensin-converting enzyme inhibitors and/or mineralocorticoid receptor antagonists. Diuretics and beta blockers are associated with greater risk of worsening of psoriatic lesions.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a psoriáza $x farmakoterapie $x komplikace $7 D011565
- 650 12
- $a hypertenze $x farmakoterapie $x komplikace $7 D006973
- 650 12
- $a antihypertenziva $x terapeutické užití $7 D000959
- 650 _2
- $a inhibitory ACE $x terapeutické užití $7 D000806
- 650 _2
- $a blokátory kalciových kanálů $x terapeutické užití $7 D002121
- 650 _2
- $a antagonisté mineralokortikoidních receptorů $x terapeutické užití $7 D000451
- 650 _2
- $a beta blokátory $x terapeutické užití $x škodlivé účinky $7 D000319
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Dodulíková, Lenka $u Department of Internal Medicine and Cardiology, University Hospital Ostrava
- 700 1_
- $a Plášek, Jiří $u Department of Internal Medicine and Cardiology, University Hospital Ostrava $u Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Ramík, Zdeněk $u Department of Internal Medicine and Cardiology, University Hospital Ostrava
- 700 1_
- $a Vrtal, Jiří $u Department of Internal Medicine and Cardiology, University Hospital Ostrava
- 700 1_
- $a Václavík, Jan $u Department of Internal Medicine and Cardiology, University Hospital Ostrava $u Centre for Research on Internal and Cardiovascular Diseases, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 773 0_
- $w MED00002723 $t Journal of hypertension $x 1473-5598 $g Roč. 43, č. 4 (2025), s. 568-576
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39976197 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134659 $b ABA008
- 999 __
- $a ok $b bmc $g 2310989 $s 1246424
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 43 $c 4 $d 568-576 $e 20250217 $i 1473-5598 $m Journal of hypertension $n J Hypertens $x MED00002723
- LZP __
- $a Pubmed-20250415
